Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery

European Journal of Clinical Pharmacology

Volumn 64, Issue 8, 2008, Pages 795-806

  Fernández Candil, Juan ^a,c   Gambús, Pedro L ^a   Trocóniz, Iñaki F ^b   Valero, Ricard ^a   Carrero, Enrique ^a   Bueno, Lorea ^b   Fábregas, Neus ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Drug interactions; NONMEM; Population PKPD; Rocuronium

Indexed keywords

PHENYTOIN; ROCURONIUM;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BRAIN SURGERY; CLINICAL ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ELECTROMYOGRAM; FEMALE; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANDROSTANOLS; ANTICONVULSANTS; DRUG INTERACTIONS; ELECTROMYOGRAPHY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUROMUSCULAR DEPOLARIZING AGENTS; NEUROSURGICAL PROCEDURES; PHENYTOIN; SOFTWARE; YOUNG ADULT;

EID: 45849089527     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0485-7     Document Type: Article

References (36)

1. Soriano SG, Martyn JA (2004) Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance. Clin Pharmacokinet 43:71-81
2. Wright PM, McCarthy G, Szenohradszky J et al. (2004) Influence of chronic phenytoin administration on the pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology 100:626-633
3. Roth S, Ebrahim ZY (1987) Resistance to pancuronium in patients receiving carbamazepine. Anesthesiology 66:691-693
4. Jellish WS, Modica PA, Tempelhoff R (1993) Accelerated recovery from pipecuronium in patients treated with chronic anticonvulsant therapy. J Clin Anesth 5:105-108
5. Hernández-Palazón J, Tortosa JA, Martinez-Lage JF et al. (2001) Rocuronium-induced neuromuscular blockade is affected by chronic phenytoin therapy. J Neurosurg Anesthesiol 13:79-82
6. Spacek A, Neiger FX, Krenn CG et al. (1999) Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. Anesthesiology 90:109-112
7. Tempelhoff R, Modica PA, Jellish WS (1990) Resistance to atracurium-induced neuromuscular blockade in patients with intractable seizure disorders treated with anticonvulsants. Anesth Analg 71:665-669
8. Richard A, Girard F, Girard DC et al. (2005) Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. Anesth Analg 100:538-544
9. Szenohradszky J, Caldwell JE, Sharma ML et al. (1994) Interaction of rocuronium (ORG 9426) and phenytoin in a patient undergoing cadaver renal transplantation: a possible pharmacokinetic mechanism? Anesthesiology 80:1167-1170
10. Viby-Mogensen J, Ostergaard D, Donati F et al. (2000) Pharmacokinetic studies of neuromuscular blocking agents: good clinical research practice (GCRP). Acta Anaesthesiol Scand 44:1169-1190
11. Szenohradszky J, Fisher DM, Segredo V et al (1992) Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology 77:899-904
12. Kleef UW, Proost JH, Roggeveld J et al. (1993) Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. J Chromatogr 621:65-76
13. Beal SL, Boeckman AJ, Sheiner LB (1998) NONMEM users guide. Part VI. PREDPP guide. Project Group, University of California at San Francisco, San Francisco
14. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokin Biopharm 20:511-528
15. Jonsson EN, Karlsson MO (1999) Xpose- and S-PLUS-based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64
16. Sheiner LB, Stanski DR, Vozeh S et al. (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371
17. Minto CF, Schnider TW, Egan TD et al. (1997) Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 86:10-23
18. Varvel JR, Donoho DL, Shafer SL (1992) Measuring the predictive performance of computer-controlled infusion pumps. J Pharmacokin Biopharm 20:63-94
19. Holford N (2005) The visual predictive check-superiority to standard diagnostic (Rorschach) plots. In: 14th Meeting of the Population Approach Group in Europe. Available at: http://www.page-meeting.org/default.asp?abstract=738
20. Minto CF, Schnider TW, Gregg KM et al. (2003) Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics. Anesthesiology 99:324-333
21. Minto C F, Schnider T W (2007) PKPD tools for Excel. Available at: www.pkpdtools.com
22. Kuipers JA, Boer F, Olofsen E et al. (2001) Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. Anesthesiology 94:47-55
23. Dragne A, Varin F, Plaud B et al. (2002) Rocuronium pharmacokinetic- pharmacodynamic relationship under stable propofol or isoflurane anesthesia. Can J Anaesth 49:353-360
24. Plaud B, Proost JH, Wierda JM et al. (1995) Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. Clin Pharmacol Ther 58:185-191
25. Abramson FP (1989) Parallel induction of plasma alpha 1-acid glycoprotein concentration and antipyrine clearance by drugs. Prog Clin Biol Res 300:427-435
26. Morita K, Yamaji A (1994) Changes in the concentration of serum alpha 1-acid glycoprotein in epileptic patients. Eur J Clin Pharmacol 46:137-142
27. Soriano SG, Sullivan LJ, Venkatakrishnan K et al. (2001) Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. Br J Anaesth 86:223-229
28. Strolin BM, Ruty B, Baltes E (2005) Induction of endogenous pathways by antiepileptics and clinical implications. Fundam Clin Pharmacol 19:511-529
29. van Mier MM, Eastwood NB, Boyd AH et al. (1997) The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Clin Pharmacol 44:139-144
30. Alloul K, Whalley DG, Shutway F et al. (1996) Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. Anesthesiology 84:330-339
31. Donati F (2000) Neuromuscular blocking drugs for the new millennium: current practice, future trends-comparative pharmacology of neuromuscular blocking drugs. Anesth Analg 90:S2-S6
32. Paul M, Fisher DM (2002) Pharmacodynamic modeling of muscle relaxants: effect of design issues on results. Anesthesiology 96:711-717
33. Plaud B, Debaene B, Donati F (2001) The corrugator supercilii, not the orbicularis oculi, reflects rocuronium neuromuscular blockade at the laryngeal adductor muscles. Anesthesiology 95:96-101
34. Schnider TW, Minto CF, Shafer SL et al. (1999) The influence of age on propofol pharmacodynamics. Anesthesiology 90:1502-1516
35. Schnider TW, Minto CF, Gambus PL et al. (1998) The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 88:1170-1182
36. Bergeron L, Bevan DR, Berrill A et al. (2001) Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology 95:314-323